admin@ataxiatelangiectasia.es
Home
Qu’est-ce que l’A-T ?
Nouvelles
Valider
News
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
Clics : 216
EryDex
Quince Therapeutics
ChromaDex wins orphan designation for rare ataxia drug
Clics : 333
EryDex
Nicotinamide Riboside
ChromaDex
FDA
Nanopore Long-Read Sequencing Facilitates Diagnosis of Atypical Ataxia-Telangiectasia
Clics : 202
Korea
late onset variant
Nanopore
Neurology Genetics
IBEC and AEFAT join forces against ataxia telangiectasia
Clics : 120
Spain
AEFAT
IBEC
Organoids to study ataxia telangiectasia
Clics : 145
Spain
IBEC
organoids
Boston Children's Hospital lab trying to develop drug to treat boy's deadly rare disease
Clics : 173
ASO
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Clics : 83
EryDex
FDA
Quince Therapeutics
Governor of Queensland Celebrates Ataxia Telangiectasia Clinical Trial
Clics : 119
Australia
Triheptanoin
Acasti reports results from ataxia telangiectasia therapy trial
Clics : 227
GTX-102
Acasti Pharma
A New Model for Neurodegenerative Disease
Clics : 124
pig model
Valider
Home
Qu’est-ce que l’A-T ?
Nouvelles
admin@ataxiatelangiectasia.es